

# Cashew nut allergy

## ImmunoCAP™ Specific IgE tests

ThermoFisher  
SCIENTIFIC

ImmunoCAP™  
Whole Allergen

ImmunoCAP™  
Allergen Components

Cashew nut (f202)

Profilin\*

PR-10\*\*

LTP\*\*

Ana o 3 (f443),  
Ana o 2\*\*\*

Profilin

PR-10

LTP

Storage proteins

### EAACI 2023 guidelines

In patients with a history of suspected IgE-mediated allergy to cashew, specific IgE to Ana o 3 is recommended in addition to skin prick test and/or IgE to extract.<sup>2</sup>

**Cashew nut and pistachio are closely related and highly cross-reactive<sup>1,3</sup>**

Ana o 3 is a good predictor for clinical reactivity to cashew & pistachio nut.<sup>4,5</sup>



### Asymptomatic<sup>1</sup> (usually)

- Labile to heat and digestion
- Highly cross-reactive with pollen and plant foods
- Low risk of reaction

### Local reactions<sup>1</sup> (mainly)

- Labile to heat and digestion
- Mainly local reactions
- Associated with birch pollen allergy (cross-reactivity)

### Local and systemic reactions<sup>1</sup>

- Stable to heat and digestion
- Associated with local and systemic reactions
- Associated with allergy to stone fruits (cross-reactivity)

### Systemic reactions<sup>1</sup>





- Stable to heat and digestion
- Associated with systemic reactions
- Indicates primary sensitisation

Cross-reactivity

Risk

\* Surrogate markers for profilin: Phl p 12, Bet v 2 or Pru p 4 \*\* No PR-10 and LTP referenced for cashew nuts in the WHO/IUIS

\*\*\* ImmunoCAP ISAC<sub>E112</sub> test only

Cashew nut (f202)	Storage protein Ana o 3	Interpreting results*	Management considerations <sup>1-7</sup>
		<b>High risk of severe, systemic symptoms<sup>1-7</sup></b>	<ul style="list-style-type: none"> <li>• Primary sensitisation to cashew nut</li> <li>• Pistachio potential co-sensitisation, Ana o 3 is a diagnostic tool also for pistachio allergy</li> <li>• Consider prescription of an adrenaline autoinjector</li> </ul>
		If all components of the algorithm are negative and f202 is positive, the patient could be sensitised to an untested allergen such as profilins, cross-reactive carbohydrate determinants (CCD) or other allergens. <sup>1</sup>	

\* Results should always be interpreted in the context of the clinical history.

**References:** **1.** Dramburg S, et al. *Pediatr Allergy Immunol.* 2023;34 Suppl 28:e13854. **2.** Santos AF, et al. *Allergy.* 2023 **3.** Van der Valk JMP, et al. *Clin Exp Allergy* 2016;47:113–120. **4.** Lange L, et al. *Allergy* 2017;72(4):598-603. **5.** Savvatanios S, et al. *J Allergy Clin Immunol* 2015;136(1):192-5. **6.** Robotham JM, et al. *J Allergy Clin Immunol* 2005;115(6):1284-1290. **7.** Kleine-Tebbe J, et al. Springer International Publishing Switzerland 2017. ISBN 978-3-319-42499-6 (e Book).

**Official product names:** ImmunoCAP Allergen f202, Cashew nut; ImmunoCAP Allergen f443, Allergen component rAna o 3, Cashew nut

 Learn more at [thermofisher.com/allergencomponents](https://thermofisher.com/allergencomponents)

© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Legal manufacturer: Phadia AB (a part of Thermo Fisher Scientific). 453351.AL.EU7.EN.V1.25